Company profile: Blue Earth Diagnostics
1.1 - Company Overview
Company description
- Provider of molecular PET imaging agents and technologies for cancer diagnosis, developing and commercialising radiopharmaceuticals addressing high unmet medical needs. Offerings include Axumin (fluciclovine F 18) for detecting recurrent prostate cancer, POSLUMA (flotufolastat F 18) Injection for detecting prostate cancer, FAP-targeted PET technology for multiple solid tumors, and clinical trials.
Products and services
- Axumin (fluciclovine F 18): Clinical-grade PET imaging agent engineered to visualize recurrent prostate cancer by exploiting increased amino acid transport in malignant cells, F 18-labeled for sensitive detection
- FAP-targeted technology: Target-specific PET imaging technology architects detection of multiple solid tumors by targeting fibroblast activation protein for visualization of tumor sites
- POSLUMA (flotufolastat F 18) Injection: Approved-use PET imaging agent produced to detect prostate cancer, flotufolastat F 18 radiotracer formulated for PET detection of prostate malignancy
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Blue Earth Diagnostics
Fusion Pharmaceuticals
HQ: Canada
Website
- Description: Provider of clinical-stage radiopharmaceuticals and targeted alpha therapies for oncology, leveraging deep radiochemistry and Fast-Clear Linker Technology to improve safety. Pipeline includes FPI-2265 targeting PSMA in prostate cancer (Phase 2), FPI-1434 targeting IGF-1R, and FPI-2059 targeting NTSR1. Offers manufacturing expertise to build commercial supply chains.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fusion Pharmaceuticals company profile →
Traws Pharma
HQ: United States
Website
- Description: Provider of clinical-stage small molecule oral therapies, including investigational inhibitors for COVID-19 (TRX01/ratutrelvir) and pandemic influenza (TRX100/tivoxavir marboxil), and narazaciclib, a proprietary multi-kinase CDK4-plus inhibitor in trials for refractory endometrial and metastatic breast cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Traws Pharma company profile →
Turning Point Therapeutics
HQ: United States
Website
- Description: Provider of structure-based drug discovery and development of precision medicines for cancer and other diseases, focusing on novel chemical identities for established oncogene drivers with secondary resistant mutations and newly identified disease-driven targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Turning Point Therapeutics company profile →
Cardiff Oncology
HQ: United States
Website
- Description: Provider of oncology therapeutics targeting cell division, including onvansertib, a PLK1 inhibitor evaluated with standard-of-care treatments for cancers such as metastatic colorectal cancer and pancreatic ductal adenocarcinoma; includes Clinical Trial CRDF-004 assessing onvansertib with standard care in KRAS- or NRAS-mutated metastatic colorectal cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cardiff Oncology company profile →
Perspective Therapeutics
HQ: United States
Website
- Description: Provider of radiopharmaceutical cancer theranostics and targeted alpha-particle radiotherapy, including Pb-203 diagnostics and Pb-212 treatment via targeting peptides. Offers clinical programs VMT-α-NET for neuroendocrine tumors and VMT01 for metastatic melanoma, and a proprietary Pb-212 isotope generator to secure key isotopes for clinical trials and commercial operations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Perspective Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Blue Earth Diagnostics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Blue Earth Diagnostics
2.2 - Growth funds investing in similar companies to Blue Earth Diagnostics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Blue Earth Diagnostics
4.2 - Public trading comparable groups for Blue Earth Diagnostics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →